. 2015 Jun 24;4(9):1448–1459. doi: 10.1002/cam4.487

Table 2.

Associations between sirolimus use and risk of specific cancer types

Cancer type	Number of studies	Cancer events		Results by study type¹		P-value for heterogeneity between study types	Combined results¹
Cancer type	Number of studies	Sirolimus group	Comparison group	Pooled incidence rate ratio (95% CI)	P-value	P-value for heterogeneity between study types	Pooled incidence rate ratio (95% CI)	P-value
Nonmelanoma skin cancer	15 RCT	91²	141²	0.49 (0.32–0.76)	<0.001	–	0.49 (0.32–0.76)	<0.001
Nonmelanoma skin cancer	0 OS	–	–	–	–	–	0.49 (0.32–0.76)	<0.001
All other cancers	17 RCTs	79	59	1.09 (0.62–1.91)	0.762	0.486	1.06 (0.69–1.63)	0.780
All other cancers	1 OS	85	787	0.94 (0.74–1.19)	0.603	0.486	1.06 (0.69–1.63)	0.780
Non-Hodgkin lymphoma	9 RCT	23	6	1.78 (0.74–4.31)	0.200	0.178	1.13 (0.63–2.03)	0.682
Non-Hodgkin lymphoma	1 OS	7	73	0.79 (0.36–1.73)	0.556	0.178	1.13 (0.63–2.03)	0.682
Kidney	8 RCT	2	15	0.19 (0.01–2.66)	0.220	0.243	0.31 (0.08–1.23)	0.096
Kidney	1 OS	9	113	0.50 (0.23–1.09)	0.081	0.243	0.31 (0.08–1.23)	0.096
Lung	8 RCT	13	2	3.69 (0.51–26.94)	0.198	0.027	1.41 (0.21–9.54)	0.723
Lung	1 OS	4	80	0.46 (0.17–1.26)	0.130	0.027	1.41 (0.21–9.54)	0.723
Prostate	8 RCT	11	3	1.92 (0.24–15.12)	0.536	0.939	1.84 (0.97–3.49)	0.061
Prostate	1 OS	21	87	1.86 (1.15–3.01)	0.012	0.939	1.84 (0.97–3.49)	0.061
Kaposi sarcoma	5 RCT	0	8	0.03 (0.00–14.03)	0.258	0.190	0.71 (0.02–26.91)	0.852
Kaposi sarcoma	1 OS	2	7	2.04 (0.40–10.35)	0.390	0.190	0.71 (0.02–26.91)	0.852

RCT, randomized controlled trial; OS, observational study.

Random effects models were used for pooled incidence rate ratio estimates.

These totals do not include events from Hoogendijk-van der Akker et al. This study did not report total cancer counts in each treatment arm, but did report the hazard ratio relating sirolimus and nonmelanoma skin cancer risk, which was used in the pooled incidence rate ratio estimation.